Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

The Chinese Market for DNA Sequencing

Posted on: 22 Sep 16

PR Newswire

NEW YORK, Sept. 22, 2016

NEW YORK, Sept. 22, 2016 /PRNewswire/ --

Use this report to:
- Learn about recent advances and trends in the Chinese sequencing industry and market.
- Analyze the Chinese sequencing market by workflow, including sample preparation products, sequencing instruments and consumables, informatics and sequencing services.
- Gain insight through profiles of Chinese companies in the sequencing industry.

- The Chinese sequencing market reached $877.6 million in 2015. The market is expected to reach nearly $2.5 billion by 2021 from $1.0 billion in 2016 increasing at a compound annual growth rate (CAGR) of 19.7% from 2016 to 2021.
- Sequencing instruments, consumables, and others as a market is expected to grow from $546.8 million in 2016 to $976.6 million in 2021 at a CAGR of 12.3% for the period 2016-2021.
- The sequencing services market over the next five years will grow from $469.2 million in 2016 to $1.5 million in 2021 at a CAGR of 26.5% for the period 2016-2021.

Introduction & Scope


The Chinese sequencing market is big, fast-growing and dominated by brands from outside of China. This market is very important for sequencing companies in North America, Europe and other developed regions that look for strong growth and high profits in the next decade. The goal of this study is to provide a comprehensive understanding of the recent advances and trends in the Chinese sequencing industry and market. This report will cover workflow (e.g., sequencers, sequencing prep and informatics) and key applications (e.g., R&D, clinical and applied) through 2021. Emphasis is placed on the Chinese next-generation sequencing (NGS) diagnostic market, which are characterized and quantified by disease indication, test complexity, test purpose and geography.

The report provides a comprehensive discussion of sequencing technologies, market applications, industry structure, marketing and distribution, partnerships andcompanies. The report is designed to aid companies in their strategic planning efforts for accessing sequencing industry opportunities in the Chinese market.

The Human Genome Project (HGP) led to significant improvements in the efficiency and costs of DNA sequencing in recent years. The costs of sequencing have rapidly reduced to the point where it is now feasible for complex NGS tests to be priced in the range of other multiplex genetic tests. As a result, opportunities for sequencing products and services are emerging in diverse applications, ranging from clinical diagnostics to agriculture genetic testing markets. The clinical value of sequencing has been shown for many applications. Chinese sequencing companies, while enjoying rapid growth, rely heavily on the technologies and instruments provided by their partners from the United States and other countries. As China?s 13 Five-Year Plan for 2016-2020 targets precision medicine as a new focus for improving the country?s health and medical standard, DNA sequencing is expected to have very fast growth in the next five years and beyond.

The scope of the report includes sequencing technologies, applications, industries, initiatives, markets and companies in China. The markets for sequencing products and services are given for the years 2015, 2016 and 2021. The report covers the Chinese sequencing market by workflow, including sample preparation products, sequencing instruments and consumables, informatics and sequencing services. It includes the Chinese sequencing instrument market by platform (i.e., Sanger and next generation technologies) and by instrument class (i.e., low throughput, high-throughput, benchtop and handheld). In this report, China is referred to Mainland China. It does not include Hong Kong, Macao and Taiwan. Mainland China has a total of 31 province-level regions, including 22 provinces, four province-level municipalities (cities) and five province-level autonomous regions. Important geographic markets will be discussed, including Beijing, Shanghai, Guangdong and others. More than 100 Chinese companies in the sequencing industry are profiled in this report.

The intended audience of this report includes sequencing equipment manufacturers, reagents, and consumables providers and sequencing services providers who are interested in the Chinese market.

Both primary (including dialogue with key industry contacts) and secondary research methodologies were used in preparing this study. Estimates of current market demand are made for 2015 and are projected over the next five years from 2016 through 2021. Projections are made in terms of constant U.S. dollars (2015), unadjusted for inflation. Growth is presented in terms of a compound average annual growth rate (CAGR).

Information sources for this report include experts, executives, professors and officials in the Chinese sequencing industry. They are from sequencing companies, associations and governmental departments. Information sources for the study also include online research, patent literature, technical journals, trade magazines, governmental data and conference papers.
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Contact Clare:
US: (339)-368-6001
Intl: +1 339-368-6001


To view the original version on PR Newswire, visit:

SOURCE Reportlinker

PR Newswire

Last updated on: 22/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.